Vascular Endothelial Growth Factor, from Basic Research to Clinical Applications
Conflicts of Interest
References
- Cao, Y.; Arbiser, J.; D’amato, R.J.; D’amore, P.A.; Ingber, D.E.; Kerbel, R.; Klagsbrun, M.; Lim, S.; Moses, M.A.; Zetter, B.; et al. Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 2011, 3, 114rv3. [Google Scholar] [CrossRef] [PubMed]
- Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 1971, 133, 275–288. [Google Scholar] [CrossRef] [PubMed]
- Clauss, M.; Gerlach, M.; Gerlach, H.; Brett, J.; Wang, F.; Familletti, P.C.; Pan, Y.C.; Olander, J.V.; Connolly, D.T.; Stern, D. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 1990, 172, 1535–1545. [Google Scholar] [CrossRef] [PubMed]
- Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306–1309. [Google Scholar] [CrossRef] [PubMed]
- Rosenthal, R.A.; Megyesi, J.F.; Henzel, W.J.; Ferrara, N.; Folkman, J. Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 1990, 4, 53–59. [Google Scholar] [CrossRef] [PubMed]
- Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983–985. [Google Scholar] [CrossRef] [PubMed]
- Shibuya, M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011, 2, 1097–1105. [Google Scholar] [CrossRef] [PubMed]
- Maglione, D.; Guerriero, V.; Viglietto, G.; Delli-Bovi, P.; Persico, M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA 1991, 88, 9267–9271. [Google Scholar] [CrossRef] [PubMed]
- Meyer, M.; Clauss, M.; Lepple, W.A.; Waltenberger, J.; Augustin, H.G.; Ziche, M.; Lanz, C.; Buttner, M.; Rziha, H.J.; Dehio, C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999, 18, 363–374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ogawa, S.; Oku, A.; Sawano, A.; Yamaguchi, S.; Yazaki, Y.; Shibuya, M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273, 31273–31282. [Google Scholar] [CrossRef] [PubMed]
- Wise, L.M.; Veikkola, T.; Mercer, A.A.; Savory, L.J.; Fleming, S.B.; Caesar, C.; Vitali, A.; Makinen, T.; Alitalo, K.; Stacker, S.A. Vascular endothelial growth factor (VEGF)-Like protein from Orf virus Nz2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. USA 1999, 96, 3071–3076. [Google Scholar] [CrossRef] [PubMed]
- De LMJunqueira-de-Azevedo, I.; da Silva, M.B.; Chudzinski-Tavassi, A.M.; Ho, P.L. Identification and cloning of snake venom vascular endothelial growth factor (svVEGF) from Bothrops erythromelas Pitviper. Toxicon 2004, 44, 571–575. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, H.; Hattori, S.; Iwamatsu, A.; Takizawa, H.; Shibuya, M. A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J. Biol. Chem. 2004, 279, 46304–46314. [Google Scholar] [CrossRef] [PubMed]
- Tokunaga, Y.; Yamazaki, Y.; Morita, T. Specific distribution of VEGF-F in viperinae snake venoms: Isolation and characterization of a VEGF-F from the venom of Daboia russelli Siamensis. Arch. Biochem. Biophys. 2005, 439, 241–247. [Google Scholar] [CrossRef] [PubMed]
- Yamazaki, Y.; Matsunaga, Y.; Nakano, Y.; Morita, T. Identification of VEGF receptor-binding protein in the venom of eastern cottonmouth: A new role of snake venom myotoxic Lys49-phospholipase A2. J. Biol. Chem. 2005, 280, 29989–29992. [Google Scholar] [CrossRef] [PubMed]
- Bry, M.; Kivela, R.; Leppanen, V.M.; Alitalo, K. Vascular endothelial growth factor-b in physiology and disease. Physiol. Rev. 2014, 94, 779–794. [Google Scholar] [CrossRef] [PubMed]
- Duchek, P.; Somogyi, K.; Jekely, G.; Beccari, S.; Rorth, P. Guidance of cell migration by the drosophila PDGF/VEGF receptor. Cell 2001, 107, 17–26. [Google Scholar] [CrossRef]
- Matthews, W.; Jordan, C.T.; Gavin, M.; Jenkins, N.A.; Copeland, N.G.; Lemischka, I.R. A receptor tyrosine kinase cdna isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA 1991, 88, 9026–9030. [Google Scholar] [CrossRef] [PubMed]
- Pajusola, K.; Aprelikova, O.; Korhonen, J.; Kaipainen, A.; Pertovaara, L.; Alitalo, R.; Alitalo, K. Flt4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res. 1992, 52, 5738–5743. [Google Scholar] [PubMed]
- Shibuya, M.; Yamaguchi, S.; Yamane, A.; Ikeda, T.; Tojo, A.; Matsushime, H.; Sato, M. Nucleotide sequence and expression of a novel human receptor- type tyrosine kinase gene (Flt) closely related to the fms family. Oncogene 1990, 5, 519–524. [Google Scholar] [PubMed]
- Terman, B.I.; Carrion, M.E.; Kovacs, E.; Rasmussen, B.A.; Eddy, R.L.; Shows, T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6, 1677–1683. [Google Scholar] [PubMed]
- Koch, S.; Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012, 2, A006502. [Google Scholar] [CrossRef] [PubMed]
- Shibuya, M. VEGF-VEGFR signals in health and disease. Biomol. Ther. 2014, 22, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Case history: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3, 391–400. [Google Scholar] [CrossRef] [PubMed]
- Aiello, L.P. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997, 29, 354–362. [Google Scholar] [CrossRef] [PubMed]
- Fogli, S.; Del, R.M.; Rofi, E.; Posarelli, C.; Figus, M.; Danesi, R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye 2018, 32, 1010–1020. [Google Scholar] [CrossRef] [PubMed]
- Krick, T.W.; Bressler, N.M. Recent clinically relevant highlights from the diabetic retinopathy clinical research network. Curr. Opin. Ophthalmol. 2018, 29, 199–205. [Google Scholar] [CrossRef] [PubMed]
- Woolard, J.; Wang, W.Y.; Bevan, H.S.; Qiu, Y.; Morbidelli, L.; Pritchard-Jones, R.O.; Cui, T.G.; Sugiono, M.; Waine, E.; Perrin, R.; et al. VEGF165b, An inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64, 7822–7835. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ballmer-Hofer, K. Vascular Endothelial Growth Factor, from Basic Research to Clinical Applications. Int. J. Mol. Sci. 2018, 19, 3750. https://doi.org/10.3390/ijms19123750
Ballmer-Hofer K. Vascular Endothelial Growth Factor, from Basic Research to Clinical Applications. International Journal of Molecular Sciences. 2018; 19(12):3750. https://doi.org/10.3390/ijms19123750
Chicago/Turabian StyleBallmer-Hofer, Kurt. 2018. "Vascular Endothelial Growth Factor, from Basic Research to Clinical Applications" International Journal of Molecular Sciences 19, no. 12: 3750. https://doi.org/10.3390/ijms19123750